Robert S. Mittleman

Learn More
AIMS To evaluate the efficacy and safety of extended dosing with mipomersen in patients with familial hypercholesterolaemia (HC) taking maximally tolerated lipid-lowering therapy. METHODS AND RESULTS A planned interim analysis of an ongoing, open-label extension trial in patients (n = 141) with familial HC receiving a subcutaneous injection of 200 mg(More)
The aim of this study to evaluate the effect of mipomersen on QT intervals in a phase I dose escalation, placebo-controlled study, and a thorough QT (tQT) study in healthy subjects. In the initial phase I study, 29 healthy subjects received either single or multiple (for 4 weeks) ascending doses of mipomersen (50–400 mg) administered subcutaneously (SC) or(More)
Mipomersen is a 20mer antisense oligonucleotide (ASO) that inhibits apolipoprotein B (apoB) synthesis; its low-density lipoprotein (LDL)-lowering effects should therefore result from reduced secretion of very-low-density lipoprotein (VLDL). We enrolled 17 healthy volunteers who received placebo injections weekly for 3 weeks followed by mipomersen weekly for(More)
Morphine administered intracerebrally (IC) (10 micrograms as the base on each side) into the MRF produced a significant dose dependent elevation of nociceptive threshold (i.e., analgesia) on the tail flick test and hemostat pinch test. However, morphine IC at lower doses had no analgesic effect. After morphine was injected IC (10 micrograms, bilaterally)(More)
  • 1